Business
Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022
Abstract Detailing TN-401 Results in PKP2 Mouse Model Accepted for Late-Breaker Oral Presentation TN-401 IND-Enabling Studies Ongoing, On Track to Submit IND
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"\nAbstract Detailing TN-401 Results in PKP2 Mouse Model Accepted for Late-Breaker Oral Presentation\n\nTN-401 IND-Enabling Studies Ongoing, On Track to Submit IND in 2023\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present new preclinical data for its TN-401 PKP2 gene therapy program at the Heart Rhythm Society’s upcoming annual Heart Rhythm 2022 meeting taking place in San Francisco, CA, and virtually. These data have been accepted for oral presentation as part of the Late-Breaking Clinical Trials: Late Breaking Science session taking place on Sunday, May 1, 2022.\n\nTN-401 is Tenaya’s gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. Mutations of the PKP2 gene are the leading genetic cause of ARVC and can result in severe disease, including significant arrhythmia and sudden cardiac death in adults and children. These mutations are estimated to affect more than 70,000 patients in the U.S. alone. TN-401 is designed to use an adeno-associated viral (AAV) vector to deliver a healthy copy of the PKP2 gene to the heart muscle of affected patients via a single intravenous dose. Tenaya has initiated IND-enabling studies for TN-401, will support the establishment of a global natural history study of ARVC caused by PKP2 mutations in 2022 and expects to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for TN-401 in 2023.\n\nDetails of the presentation are as follows:\n\nSunday, May 1, 2022\n9:15 a.m.-10:15 a.m. PT\nLate-Breaking Clinical Trials: Late Breaking Science session\nOral Presentation: Cardiac AAV:PKP2 Gene Therapy Reduces Ventricular Arrhythmias, Reverses Adverse Right Ventricular Remodeling, Improves Heart Function, and Extends Survival in a Pkp2-Deficient Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy (Abstract 7263)\nLead author: Jane Yang, Ph.D., Senior Scientist, Tenaya Therapeutics\n\nTo view full event programming, please visit the Heart Rhythm 2022 website.\n\nAbout Tenaya Therapeutics\n\nTenaya Therapeutics is a biotechnology company committe...